391 Followers on Owler


Read more
Gabriel Baertschi's photo - Chairman & CEO of Grunenthal

Chairman & CEO

Gabriel Baertschi

CEO Approval Rating





PrivateIndependent Company









Missing a competitor? Contribute!

Endo is one of Grunenthal's top competitors. Endo was founded in 1997 in Ballsbridge, County Dublin. Like Grunenthal, Endo also operates in the Pharmaceuticals industry. Endo generates $1.2B more revenue than Grunenthal.

UCB is a top competitor of Grunenthal. UCB was founded in 1928, and is headquartered in Brussels, Brussels-Capital Region. UCB operates in the Biotechnology industry. UCB generates $5B more revenue vs. Grunenthal.

Salix Pharmaceuticals is seen as one of Grunenthal's top competitors. Salix Pharmaceuticals is headquartered in Bridgewater, New Jersey, and was founded in 1989. Like Grunenthal, Salix Pharmaceuticals also competes in the Pharmaceuticals field. Salix Pharmaceuticals generates 63% the revenue of Grunenthal.

Grunenthal Acquisitions

Mestex AG

Apr 2021

Source »
Mestex is a Switzerland-based biotech company that develops and commercializes investigational medicines for the treatment of osteoarthritis.
Averitas Pharma, Inc.

Nov 2018

Source »
Averitas Pharma is a pharmaceutical company that researches and develops novel therapeutics for the non-opioid treatment of acute pain.
Adhesys Medical GmbH

Apr 2017

Source »
Adhesys is a medical device company that focuses on developing polyurethane-based surgical sealants for emergency procedures.
Thar Pharmaceuticals Inc

Nov 2016

Source »
Thar Pharmaceuticals researches, discovers, develops and commercializes oral therapies for serious and life threatening conditions.


Almirall de Mexico

Mar 2016

Source »

These are all the companies that Grunenthal has acquired. Grunenthal has acquired 5 companies and its latest acquisition was Mestex AG in Apr 2021. Mestex is a Switzerland-based biotech company that develops and commercializes investigational medicines for the treatment of osteoarthritis.

Grunenthal Funding History

No recent funding data found related to Grunenthal

Grunenthal Investments

No recent investments found related to Grunenthal

These are all the companies that Grunenthal has invested in. Grunenthal has invested 5 companies and its latest investment was Mestex AG in Apr 2021. Mestex is a Switzerland-based biotech company that develops and commercializes investigational medicines for the treatment of osteoarthritis.

Grunenthal News

April 23, 2021MarketScreener

announces pricing of its first bond

(marketscreener.com) DGAP-News: Grünenthal GmbH / Key word: Bond Grünenthal announces pricing of its ... See more »
April 15, 2021Global Legal Chronicle

Grnenthal GmbH's Acquisition of Mestex AG

Homburger advises Grünenthal GmbH on this matter. Grünenthal GmbH announced the acquisition of Mestex... See more »
April 14, 2021startupticker

Grnenthal acquires Swiss biotech company Mestex

With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asse... See more »
April 6, 2021FinanzNachrichten

Grnenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks

- Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among ... See more »
February 12, 2021FinanzNachrichten

Grnenthal successfully extends its term loan bank facilities

AACHEN, Germany, Feb. 12, 2021 /PRNewswire/ -- Grünenthal has announced the successful extension of i... See more »
February 10, 2021Markets Insider

Grnenthal closes deal with AstraZeneca for European rights to CRESTOR (rosuvastatin)

AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ -- Grünenthal today announced the successful completion o... See more »
February 8, 2021Royal Pharmaceutical Society

Grnenthal Ltd, Palexia 20 mg/ml Oral Solution

Grünenthal Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that it is... See more »

Grunenthal Press Releases

May 2, 2019PR Newswire

Five Young Scientists Win EFIC-Grünenthal Grant 2018

BRUSSELS and AACHEN, Germany, May 2, 2019 /PRNewswire/ -- The European Pain Federation EFIC® and the ... See more »
June 18, 2018PR Newswire

Fresh Ideas in Pain Research

DIEGEM, Belgium and AACHEN, Germany, June 18, 2018 /PRNewswire/ -- Creative approaches to research by... See more »
June 15, 2018PR Newswire

Grünenthal Selected as One of the Best Employers in Europe for the Third Time

AACHEN, Germany, June 15, 2018 /PRNewswire/ -- Grünenthal has qualified as one of the 25 Best Multina... See more »
February 1, 2018ForImmediateRelease

Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

Travel & Tourism Industry release: AACHEN, Germany, February 1, 2018 /PRNewswire/ - Grünenthal announ... See more »
December 5, 2017ForImmediateRelease

New Partnership for the Commercialization of Nucynta® in the U.S. Territory

Travel & Tourism Industry release: AACHEN, Germany, December 5, 2017 /PRNewswire/ - The Grünenthal Gr... See more »
November 16, 2017PR Newswire

Research Consortium led by Grünenthal Receives € 2 Million Grant from the European Fund for Regional Development and the State of North Rhine-Westphalia

AACHEN, Germany, November 16, 2017 /PRNewswire/ -- - "LifeSciences.NRW" grant to support the discover... See more »
October 31, 2017Business Wire

Diabetic Neuropathic Pain - Global Clinical Trials Review, H2, 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Diabetic Neuropathic Pain Global Clinical Trials Review, H2, 2017" clin... See more »

Social Media

Grunenthal Headquarters

Zieglerstrasse 6

Aachen, North Rhine-Westphalia52099


Driving Directions »

Trending Companies

Grunenthal Summary



Grunenthal Group is a research and development pharmaceutical company that focuses on pain treatments. Grunenthal was founded in 1946. Grunenthal's headquarters is located in Aachen, North Rhine-Westphalia, DE 52099. Grunenthal's Chairman & CEO, Gabr...


Grunenthal's Chairman & CEO, Gabriel Baertschi, currently has an approval rating of 76%. Grunenthal's primary competitors are Endo, UCB & Salix Pharmaceuticals.

Frequently Asked Questions about Grunenthal

  1. When was Grunenthal founded?

    Grunenthal was founded in 1946
  2. Who is Grunenthal's CEO?

    Grunenthal's CEO is Gabriel Baertschi
  3. How much revenue does Grunenthal generate?

    Grunenthal generates $1.6B in revenue
  4. How much funding does Grunenthal have?

    Grunenthal has historically raised $0 in funding
  1. Where is Grunenthal's headquarters?

    Grunenthal's headquarters is in Aachen North Rhine-Westphalia, DE
  2. How many employees does Grunenthal have?

    Grunenthal has 4,500 employees
  3. What sector does Grunenthal operate in?

    Grunenthal is in Pharmaceuticals
  4. Who are Grunenthal's competitors?

    Grunenthal's top competitors are Endo, UCB, Salix Pharmaceuticals